Thrombocytopenia possibly associated with olanzapine and subsequently with benztropine mesylate.
Bogunovic
O
O
Department of Psychiatry, State University of New York Health Science Center at Brooklyn 11203, USA.
Viswanathan
R
R
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D001590:Benztropine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000077152:Olanzapine; D010276:Parasympatholytics / Q000009:adverse effects* / Q000627:therapeutic use; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010976:Platelet Count / Q000187:drug effects; D011618:Psychotic Disorders / Q000097:blood / Q000188:drug therapy*; D012008:Recurrence; D013921:Thrombocytopenia / Q000139:chemically induced*
D014150:Antipsychotic Agents; D010276:Parasympatholytics; D001569:Benzodiazepines; D001590:Benztropine; D010890:Pirenzepine; D000077152:Olanzapine